Article

Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer.

Department of Oncology and Radiation Physics, Sahlgrenska University Hospital in Gothenburg, Sweden.
Acta Oncologica (impact factor: 3.33). 02/2006; 45(7):973-7. DOI:10.1080/02841860600919241 pp.973-7
Source: PubMed

ABSTRACT In forthcoming multicentre studies on stereotactic body radiotherapy (SBRT) compliance with volume and dose prescriptions will be mandatory to avoid unnecessary heterogeneity bias. To evaluate compliance in a multicentre setting we used two cases from an ongoing phase II study of SBRT of T1-T2N0M0 inoperable NSCLC in a dummy run oriented on volumes and doses. Six Scandinavian centres participated. Each centre received CT-scans covering the whole lung volumes of two patients with instructions to follow the study protocol when outlining tumour and target volumes, prescribing doses and creating dose plans. Volumes and doses of the 12 dose plans were evaluated according to the study protocol. For the two patients the GTV volume range was 24 to 39 cm3 and 26 to 41 cm3, respectively. The PTV volume range was 90 to 116 cm3, and 112 to 155 cm3, respectively. For all plans the margin between CTV and PTV in all directions followed in detail the protocol. The prescribed dose was for all centres 45 Gy/3 fractions (isocentre dose about 66 Gy). The mean GTV doses ranged from 63 to 67 Gy and from 63 to 68 Gy, respectively. The minimum doses for GTV were between 50-64 Gy and between 55-65 Gy, respectively. The dose distribution was conformed to PTV for 10 of 12 plans and 2 of 12 plans from one centre had sub-optimal dose distribution. Most of the volume and dose parameters for the participating centres showed fully acceptable compliance with the study protocol.

0 0
 · 
0 Bookmarks
 · 
24 Views

Keywords

12 dose plans
 
acceptable compliance
 
centres 45 Gy/3 fractions
 
dose parameters
 
dose prescriptions
 
forthcoming multicentre studies
 
GTV volume range
 
isocentre dose
 
mean GTV doses
 
minimum doses
 
ongoing phase II study
 
participating centres
 
prescribed dose
 
prescribing doses
 
PTV volume range
 
Scandinavian centres
 
target volumes
 
two patients
 
unnecessary heterogeneity bias
 
whole lung volumes